Buy Kineret in India — Price & Availability

What is Kineret used for?

Kineret (anakinra) is a recombinant form of the human interleukin-1 receptor antagonist. Interleukin-1 (IL-1) is a protein that drives inflammation; by blocking the IL-1 receptor, Kineret reduces the excess inflammation seen in certain autoinflammatory and rheumatic conditions.

It is approved for:

• Rheumatoid arthritis (RA) — to reduce signs and symptoms and slow structural joint damage in moderately to severely active RA in adults 18 years and older who have failed one or more disease-modifying antirheumatic drugs (DMARDs). It can be used alone or with DMARDs other than TNF-blocking agents.
• Neonatal-Onset Multisystem Inflammatory Disease (NOMID) — a form of Cryopyrin-Associated Periodic Syndromes (CAPS).
• Deficiency of Interleukin-1 Receptor Antagonist (DIRA).

It is contraindicated in patients with known hypersensitivity to E. coli-derived proteins or to any component of the product. It is a prescription medicine and must be used under the supervision of a qualified physician.

Recommended dosage:
Kineret is given as a subcutaneous (SC) injection, and the dose depends on the condition:

• Rheumatoid arthritis: 100 mg once daily, given at about the same time each day. A dose of 100 mg every other day may be considered for RA patients with severe renal impairment or end-stage renal disease.
• NOMID: a weight-based starting dose of 1–2 mg/kg once daily, adjusted in 0.5–1 mg/kg increments to control disease, up to a maximum of 8 mg/kg daily. The daily dose may be split into two injections.
• DIRA: dosed by body weight as directed by the treating doctor.

Each prefilled syringe is single-use; a new syringe is used for each dose, and injection sites are rotated. The treating physician always determines the exact dose.

• Serious infections: Kineret has been associated with an increased risk of serious infections; it should not be started in patients with active infection, and treatment is discontinued in RA if a serious infection develops. The combination of Kineret with TNF-blocking agents is not recommended due to increased infection risk.
• Hypersensitivity reactions: allergic reactions can occur; DIRA patients may have an increased risk, particularly in the first several weeks.
• Injection-site amyloidosis: rotating injection sites is recommended to reduce the risk of injection-site amyloid deposits.
• Neutropenia: neutrophil counts are checked before starting and periodically during treatment.
• Immunosuppression and vaccines: live vaccines should not be given at the same time as Kineret.

Common side effects:
The most common side effects (incidence ≥ 5%) include injection-site reactions, along with headache, worsening of rheumatoid arthritis, and upper respiratory infections. This is not a complete list — refer to the full prescribing information and your doctor.

Patients in India can legally access Kineret through the Named Patient Program (NPP) — an import route that allows a medicine not yet registered in India to be imported in an individual patient’s name, on their physician’s prescription. The process is simple and fully documented:

• Share your request — the patient or treating doctor sends the medicine name, required quantity, and destination city.
• Eligibility & document check — we verify the prescription, diagnostic reports, and patient ID against regulatory requirements.
• Receive your quote — a transparent quotation covering medicine cost, logistics, and timeline.
• Regulatory approvals — we assist with the import permit and documentation needed for legal cross-border access.
• Cold-chain import & delivery — Kineret is sourced and shipped under validated 2–8 °C conditions to the patient or treating hospital.

Documents required to import Kineret:

• A valid prescription from a qualified physician
• The patient’s diagnostic reports
• Government-issued patient ID proof
• An import permit, where applicable

Because Kineret is not sold on the open market in India, there is no fixed MRP. The Kineret cost in India depends on a few factors at the time of import:

• The number of prefilled syringes required, which is based on the prescribed daily dose and treatment duration (in rheumatoid arthritis, the usual dose is 100 mg once daily; weight-based dosing applies in NOMID).
• The sourcing country and current ex-market price (USA, Europe, Canada, Japan, China, or Australia).
• Cold-chain logistics, insurance, and any applicable customs duties or import permit costs

Get a transparent quote: We provide a written quotation covering Kineret cost, logistics, and delivery timeline once a valid prescription is shared. Request your Kineret quote →

Kineret is a prescription-only medicine. Pricing is shared with patients, caregivers, and treating hospitals against a valid prescription, in line with applicable regulations.

Indian Pharma Network sources Kineret from reliable manufacturers and authorised supply channels and facilitates supply to patients, doctors, and hospitals under applicable legal provisions. As a temperature-sensitive biologic, Kineret prefilled syringes require cold-chain handling: stored refrigerated at 2 °C–8 °C, protected from light, and never frozen or shaken. All orders are dispensed and checked by registered pharmacists and dispatched after legal requirements are fulfilled.

Is Kineret available in India?

Kineret (anakinra injections) is a prescription medicine that legally requires a doctor’s prescription to be dispensed. As of current publicly available information, Kineret is not commercially marketed in India.

However, patients in India can legally access Kineret through the Named Patient Program (NPP) — an import provision that allows a medicine not yet registered in India to be imported in the name of an individual patient, on the prescription of their treating physician.

Indian Pharma Network (IPN) acts as a facilitator under named patient supply, providing input on:

• Availability of Kineret in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.) and pathways to access it
• Availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
  Kineret price in India under the NPP route
• Sourcing from genuine, reliable channels in the USA, Canada, Europe, and Australia
• Ensuring full transparency throughout the process

Kineret can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient’s treating hospital. Orders are confirmed only upon receipt of a valid doctor’s prescription and, where applicable, an import permit.

Regulatory approval status:
Kineret first received US FDA approval in 2001 for rheumatoid arthritis, with later approvals for Neonatal-Onset Multisystem Inflammatory Disease (NOMID) and Deficiency of Interleukin-1 Receptor Antagonist (DIRA). It is also approved in the European Union and other markets. As of the current publicly available information, Kineret is not commercially marketed in India, which is why the Named Patient route is used.